Dividend stocks are not all the same. Some will readily decrease or suspend their payouts at the first sign of trouble, while others will continue increasing them even during market downturns or economic recessions.
Dividend investors prefer those that are in the latter category. Let’s consider two stocks along those lines that are worth buying: Johnson & Johnson (NYSE: JNJ) and Zoetis (NYSE: ZTS). These two healthcare companies are excellent picks for income-oriented investors.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Johnson & Johnson has many qualities that long-term income seekers seek. The company’s business, albeit not particularly exciting, is consistent and resilient. Johnson & Johnson is a leading pharmaceutical company with a vast portfolio of approved medicines, as well as a medical device leader operating across several therapeutic areas.
Revenue and earnings typically grow at a decent clip. That’s the case even when it encounters problems such as patent cliffs and government-led drug price negotiations — issues it is currently dealing with, but it expects its annual reported sales to grow this year and top $100 billion for the first time. Johnson & Johnson also has a rock-solid balance sheet, evidenced by its higher credit rating than the U.S. government’s.
Further, Johnson & Johnson is an innovative company. It routinely launches new products, both in its biopharma and medtech divisions, that help it counter stiff competition, whether biosimilar or otherwise.
Johnson & Johnson is now awaiting approval for its robotic-assisted surgery system, the Ottava, that could be an important growth driver over the long run. And the company’s pharmaceutical pipeline features several dozen ongoing clinical trials that will help it replenish its portfolio and earn important label expansions.That’s how the company has performed well over the long run.
Finally, Johnson & Johnson is a Dividend King, a company with at least 50 consecutive annual dividend hikes. That’s what helps make it an outstanding income stock that dividend investors shouldn’t think twice about.
Zoetis is a leading animal health company. It hit some headwinds last year, as two of its growth drivers, Librela and Solensia, which treat osteoarthritis (OA) pain in dogs and cats, respectively, raised safety concerns; this issue particularly affected Librela.
